BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
188.15
+1.15 (+0.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close187.00
Open187.55
Bid187.50 x 800
Ask188.45 x 800
Day's range181.10 - 189.00
52-week range74.45 - 236.17
Volume571,840
Avg. volume715,909
Market cap9.43B
Beta2.88
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • What Analysts Think about Ionis
    Market Realist14 hours ago

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
    Motley Fool2 days ago

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio

    Which stock wins in a head-to-head match-up between these two clinical-stage biotechs?

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist8 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.
    Motley Fool14 days ago

    Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.

    Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?

  • bluebird bio Looks for Data Ahead
    Motley Fool16 days ago

    bluebird bio Looks for Data Ahead

    An uneventful first quarter, but the biotech has data coming later in the year.

  • Associated Press23 days ago

    Bluebird: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.31. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...

  • 2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
    Motley Foollast month

    2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line

    New treatments could be coming from Celgene and bluebird bio that reshape how we treat this life-threatening gene disorder.

  • Is bluebird bio One Step Closer to Its First Commercial Drug?
    Motley Foollast month

    Is bluebird bio One Step Closer to Its First Commercial Drug?

    Interim results for one of its lead gene therapies could suggest an approval in the future

  • The Wall Street Journallast month

    Gene Therapy Shows Promise in Patients with a Blood Disorder

    Researchers successfully used an experimental gene therapy developed by biotech company Bluebird Bio Inc. to reduce the number of blood transfusions needed in people with beta-thalassemia, an inherited ...

  • Is bluebird bio, Inc. a Buy on the Dip?
    Motley Foollast month

    Is bluebird bio, Inc. a Buy on the Dip?

    Biotech stocks can be awfully risky. Find out if this one's worth the anxiety.

  • Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics
    Market Realistlast month

    Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

    Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.

  • Why Omeros Stock Rose Last Week
    Market Realistlast month

    Why Omeros Stock Rose Last Week

    In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
    Motley Fool2 months ago

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio

    Both biotechs are developing next generation gene therapies, but only one company is a clear cut buy.

  • 3 Top Biotech Stocks to Buy in April
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy in April

    Biotech stocks are falling, and that could be creating an opportunity to buy shares in these top companies.

  • Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
    Market Realist2 months ago

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

  • Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate
    Zacks2 months ago

    Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate

    Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.

  • Exploring the Financial Performance of Akcea Therapeutics
    Market Realist2 months ago

    Exploring the Financial Performance of Akcea Therapeutics

    The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.

  • Analysts’ Recommendations for Akcea and Its Peers in March
    Market Realist2 months ago

    Analysts’ Recommendations for Akcea and Its Peers in March

    Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.

  • This Is My Favorite Biotech Stock To Buy On Sale
    Motley Fool2 months ago

    This Is My Favorite Biotech Stock To Buy On Sale

    The potential to leap from clinical-stage to commercial-stage biotech makes this my top pick right now.

  • Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
    Zacks2 months ago

    Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

    Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

  • Reuters3 months ago

    Why Oppenheimer Global fund is focusing on biotech as rates rise

    The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc (SAGE.O), Bluebird Bio Inc (BLUE.O) and Ionis Pharmaceuticals Inc (IONS.O) whose drugs can have multiple uses rather than pinpointing a specific ailment.

  • Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
    Zacks3 months ago

    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

  • 3 Big Drugmakers Boosting Huge R&D Budgets
    Motley Fool3 months ago

    3 Big Drugmakers Boosting Huge R&D Budgets

    These three biopharmaceutical companies boosted their R&D budgets by more than $1 billion last year. Will it pay off for investors?

  • bluebird bio Updates Plans for the Year Ahead
    Motley Fool3 months ago

    bluebird bio Updates Plans for the Year Ahead

    The gene therapy company is on the precipice of applying for approval for its first drug.

  • Associated Press3 months ago

    Bluebird reports 4Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.52. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes